The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. CTAF convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the CTAF process, and find out how topics are selected.
CTAF directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the CTAF Panel must meet ICER’s criteria for Conflict of Interest.
For CTAF reports published prior to September 2013, please email firstname.lastname@example.org
The box below provides information on the topic of the next meeting of CTAF. For more information about past and other upcoming meetings, see the box to the right.
Preservation Park (Nile Hall)
1233 Preservation Park Way
Oakland CA, 94612
ICER will develop a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. ICER’s report will consider the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM , Novartis) and axicabtagene ciloleucel (YescartaTM, Kite Pharma). Both agents were approved in 2017. Tisagenlecleucel is approved for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients. Novartis is also expected to file later this year for a second indication for diffuse large B-cell lymphoma in adults. Axicabtagene ciloleucel is approved for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in adult patients.
Date of Review: March 2018View materials